Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial

Maximilien Vermandel, Clément Dupont, Fabienne Lecomte, Henri Arthur Leroy, Constantin Tuleasca, Serge Mordon, Constantinos G. Hadjipanayis, Nicolas Reyns

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

Purpose: Glioblastoma (GBM) is the most aggressive malignant primary brain tumor. The unfavorable prognosis despite maximal therapy relates to high propensity for recurrence. Thus, overall survival (OS) is quite limited and local failure remains the fundamental problem. Here, we present a safety and feasibility trial after treating GBM intraoperatively by photodynamic therapy (PDT) after 5-aminolevulinic acid (5-ALA) administration and maximal resection. Methods: Ten patients with newly diagnosed GBM were enrolled and treated between May 2017 and June 2018. The standardized therapeutic approach included maximal resection (near total or gross total tumor resection (GTR)) guided by 5-ALA fluorescence-guided surgery (FGS), followed by intraoperative PDT. Postoperatively, patients underwent adjuvant therapy (Stupp protocol). Follow-up included clinical examinations and brain MR imaging was performed every 3 months until tumor progression and/or death. Results: There were no unacceptable or unexpected toxicities or serious adverse effects. At the time of the interim analysis, the actuarial 12-months progression-free survival (PFS) rate was 60% (median 17.1 months), and the actuarial 12-months OS rate was 80% (median 23.1 months). Conclusions: This trial assessed the feasibility and the safety of intraoperative 5-ALA PDT as a novel approach for treating GBM after maximal tumor resection. The current standard of care remains microsurgical resection whenever feasible, followed by adjuvant therapy (Stupp protocol). We postulate that PDT delivered immediately after resection as an add-on therapy of this primary brain cancer is safe and may help to decrease the recurrence risk by targeting residual tumor cells in the resection cavity. Trial registration NCT number: NCT03048240. EudraCT number: 2016-002706-39. Graphic abstract: [Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)501-514
Number of pages14
JournalJournal of Neuro-Oncology
Volume152
Issue number3
DOIs
StatePublished - May 2021
Externally publishedYes

Keywords

  • 5-ALA
  • Clinical trial
  • Glioblastoma
  • Intraoperative MRI
  • Photodynamic therapy

Fingerprint

Dive into the research topics of 'Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial'. Together they form a unique fingerprint.

Cite this